Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results ...

IRVINE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

Proscia sells digital pathology software and artificial intelligence tools to pharmaceutical companies and diagnostic ...

While the allogeneic vs autologous debate continues in the cell therapy field, research on in vivo therapies is drawing ...

(Tune Photo) — Tune Therapeutics named Dr. John McHutchison ... years and prior to IonQ was director of engineering at Amazon Prime. — Shiftboard, a Seattle company providing workforce ...

CRISPR Therapeutics AG (CRSP)’s share was trading ... competitors are developing alternative gene-editing approaches, such as base and prime editing, that could challenge CRSP’s leadership.

India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and targeted oncology company, for $355 million.

A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, AlbionVC, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management ...

Learn more about whether Kymera Therapeutics, Inc. or Ultragenyx Pharmaceutical Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.